| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.7326/0003-4819-152-9-201005040-00008 |
| P698 | PubMed publication ID | 20439576 |
| P50 | author | Marc Carrier | Q79441213 |
| P2093 | author name string | Marc A Rodger | |
| Philip S Wells | |||
| Grégoire Le Gal | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| venous thromboembolism | Q9397786 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 578-589 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism | |
| P478 | volume | 152 |
| Q38002155 | A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism |
| Q33440651 | A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients |
| Q37368820 | A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis |
| Q41118456 | ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention |
| Q37772221 | Ambulatory management of pulmonary embolism: a pragmatic evaluation |
| Q37588677 | Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism |
| Q90029392 | Anticoagulating patients with high-risk acquired thrombophilias |
| Q92424363 | Anticoagulation in pulmonary arterial hypertension: a decision analysis |
| Q24633053 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q38088605 | Aspirin and recurrent venous thromboembolism |
| Q33841714 | Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism |
| Q35987865 | Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism |
| Q64242328 | Association of recurrent venous thromboembolism and circulating microRNAs |
| Q45865721 | Athletes and blood clots: individualized, intermittent anticoagulation management |
| Q90029384 | Breadth of complications of long-term oral anticoagulant care |
| Q38388643 | Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. |
| Q39875454 | Central Versus Peripheral Pulmonary Embolism: Analysis of the Impact on the Physiological Parameters and Long-term Survival |
| Q91153929 | Cessation of anticoagulation therapy following endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis |
| Q38117418 | Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications |
| Q90270037 | Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews |
| Q43978668 | Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials |
| Q58701249 | Cost-effectiveness analysis of five procedures for great saphenous vein reflux in a Norwegian healthcare setting or societal setting |
| Q33637113 | Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis |
| Q93092328 | D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding |
| Q37648653 | D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. |
| Q34262668 | Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial |
| Q35559025 | Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009). |
| Q30249169 | Deep vein thrombosis and pulmonary embolism |
| Q47996847 | Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study |
| Q45847579 | Diagnosis and anticoagulant treatment |
| Q24633090 | Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q34078303 | Diet as prophylaxis and treatment for venous thromboembolism? |
| Q37949309 | Difficulties in diagnosing pulmonary embolism in the obese patient: a literature review |
| Q92654796 | Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study |
| Q38851927 | Drug Treatment of Venous Thromboembolism in the Elderly. |
| Q34254243 | Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. |
| Q34284224 | Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term |
| Q45910165 | Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. |
| Q24194466 | Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism |
| Q27027477 | Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis |
| Q38133389 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis |
| Q90029367 | Elite athletes and anticoagulant therapy: an intermittent dosing strategy |
| Q40058129 | Excess risk of venous thromboembolism in hip fracture patients and the prognostic impact of comorbidity. |
| Q90480757 | Extended anticoagulation for unprovoked venous thromboembolism |
| Q45870309 | External validation of the DASH prediction rule: a retrospective cohort study. |
| Q45160607 | Family history of venous thromboembolism (VTE) as a predictor for recurrent VTE in unprovoked VTE patients. |
| Q47554769 | Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients |
| Q36195033 | Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism |
| Q33590496 | Five-year follow-up of pulmonary embolism under anticoaugulation: The PISA-PEET (Pulmonary Embolism Extension Therapy) study |
| Q28078989 | Guidance for the treatment of deep vein thrombosis and pulmonary embolism |
| Q51220285 | Identification of Genetic Aberrations in Thrombomodulin Gene in Patients With Recurrent Venous Thromboembolism. |
| Q41216205 | Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study |
| Q36282297 | Improving venous thromboembolism (VTE) prophylaxis in acute urological admissions during out of hours through the introduction of a urological admission proforma |
| Q94062366 | Improving venous thromboembolism risk assessment rates in a tertiary Ear, Nose and Throat Department |
| Q34462703 | Inferior vena cava filters: current best practices |
| Q30664606 | Inferior vena cava filtration in the management of venous thromboembolism: filtering the data |
| Q37697342 | Inherited Thrombophilia in Pediatric Venous Thromboembolic Disease: Why and Who to Test |
| Q38805424 | Intracranial hemorrhage in cancer patients treated with anticoagulation |
| Q42109689 | Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban |
| Q52618592 | Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. |
| Q53076717 | Lack of association between airflow limitation and recurrence of venous thromboembolism among cancer patients with pulmonary embolism. |
| Q92152596 | Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis |
| Q41849650 | Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis |
| Q44481789 | Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry |
| Q26828750 | Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis |
| Q38049617 | Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach |
| Q36718482 | Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach |
| Q38093286 | Management of venous thromboembolism--controversies and the future |
| Q92518274 | Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis |
| Q87015681 | New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction? |
| Q40928535 | Occurrence and predictors of recurrence after a first episode of acute venous thromboembolism: population-based Worcester Venous Thromboembolism Study |
| Q35210139 | Optimal duration of anticoagulation in patients with venous thromboembolism. |
| Q47959251 | Optimal long-term pharmacological treatment of patients with venous thromboembolism that was unprovoked or associated with weak risk factors |
| Q38117732 | Optimal treatment duration of venous thrombosis. |
| Q53767247 | Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. |
| Q33692054 | Perioperative management of patients on direct oral anticoagulants. |
| Q38117546 | Perioperative management of patients who are receiving a novel oral anticoagulant. |
| Q38779161 | Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery |
| Q33692552 | Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. |
| Q38777127 | Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis |
| Q39029202 | Pharmacological management of pulmonary embolism |
| Q57172953 | Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner |
| Q47923995 | Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). |
| Q41486100 | Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. |
| Q49989217 | Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold. |
| Q95537463 | Pulmonary embolism |
| Q38042025 | Pulmonary embolism: risk assessment and management |
| Q38939453 | Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed |
| Q28067358 | Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed |
| Q38569212 | Recent developments in the diagnosis and treatment of pulmonary embolism. |
| Q36715886 | Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. |
| Q33734478 | Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience. |
| Q26826847 | Recurrent venous thromboembolism: what is the risk and how to prevent it |
| Q33821311 | Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. |
| Q95474827 | Risk assessment for recurrent venous thrombosis |
| Q34153343 | Risk assessment for recurrent venous thrombosis |
| Q37075924 | Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism |
| Q55353518 | SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. |
| Q44646049 | Safety of outpatient treatment in acute pulmonary embolism. |
| Q50699940 | Safety of ventilation/perfusion single photon emission computed tomography for pulmonary embolism diagnosis. |
| Q33396864 | Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation |
| Q24197581 | Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism |
| Q47304199 | Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. |
| Q35201524 | Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis |
| Q49989172 | Symptomatic subsegmental pulmonary embolism: to treat or not to treat? |
| Q38016569 | Symptomatic subsegmental pulmonary embolism: what is the next step? |
| Q51515902 | The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism. |
| Q34866266 | The Saudi clinical practice guideline for the diagnosis of the first deep venous thrombosis of the lower extremity |
| Q37823406 | The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management |
| Q41685100 | The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study |
| Q53546563 | The short-term efficacy of vena cava filters for the prevention of pulmonary embolism in patients with venous thromboembolism receiving anticoagulation: Meta-analysis of randomized controlled trials. |
| Q39350630 | Therapeutic management of acute pulmonary embolism |
| Q33840400 | Thromboembolism. |
| Q40993089 | Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism |
| Q36561057 | Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management |
| Q49588088 | Treatment of venous thromboembolism in a 22-year-old woman taking an oral contraceptive pill |
| Q26782483 | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| Q38815146 | Using the laboratory to predict thrombosis in dogs: An achievable goal? |
| Q40287097 | Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study |
| Q26825608 | Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation |
| Q47340294 | When can we stop anticoagulation in patients with cancer-associated thrombosis? |
| Q37843743 | Which patients with unprovoked VTE should receive extended anticoagulation? the minority |
| Q26849407 | Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority |
| Q45866145 | Who should be tested for thrombophilia? |
| Q59133386 | Who should get long-term anticoagulant therapy for venous thromboembolism and with what? |
| Q90029379 | Who should get long-term anticoagulant therapy for venous thromboembolism and with what? |
| Q33997674 | XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. |
| Q87913565 | [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology] |
| Q53183195 | [Should we treat subsegmental pulmonary embolism?]. |
Search more.